HIV

About 40% of people living with HIV in an international survey did not make joint decisions regarding treatment with their provider despite reporting a high amount of trust.

People living with HIV who have taken highly active antiretroviral therapy can have hyperlipidemia predicted in advance by machine learning.

A panelist discusses how HIV treatment has evolved with tremendous improvements in efficacy, tolerability, and convenience, with exciting developments at the Conference on Retroviruses and Opportunistic Infections 2025, including new long-acting therapies for treatment and prevention that could last up to 2 years.

Sleep disorders and mental health complications were more common in adolescents or young adults who had HIV across the globe.

A panelist discusses how CD4 counts serve as measures of immune system status that typically increase by about 200 in the first year of antiretroviral therapy. Although there can be laboratory variability, these counts remain important for patient monitoring and identifying those at risk for complications.

A panelist discusses how the injectable combination of cabotegravir and rilpivirine performed well in the real-world OPERA cohort, with over 95% of patients maintaining virologic suppression. However, adherence to injection schedules remains a challenge, with only 62% receiving injections on time.

The CDC uses molecular cluster detection to find the transmission of HIV that could pinpoint where there are gaps in HIV care.

Patients with HIV can take both their antiretroviral therapy (ART) and treatment to prevent tuberculosis safely to prevent infection and further spread of the virus.

The ability to estimate their last viral load was high among women with HIV living in British Columbia, even in those with adverse sociodemographic factors.

A panelist discusses how the new doravirine and islatravir combination offers an alternative to integrase inhibitor-based therapies, particularly useful for patients with integrase inhibitor resistance or adverse reactions, although clinicians may struggle with determining the ideal patient population.

A panelist discusses how a new drug combination of doravirine and islatravir was compared to a standard bictegravir-based therapy in patients with HIV, showing noninferiority with over 90% of patients maintaining viral suppression without excess toxicity.

These guidelines act as an update to the 2016 guidelines for the use of nonoccupational postexposure prophylaxis (PEP) after exposure to HIV.

Viral suppression in HIV was more likely to be reported in women in Canada who had adherence to their antiretroviral therapy (ART) of 90% or higher.

Correlation to social drivers of health (SDOH) had an important correlation with polysubstance use.

A panelist discusses how the HIV patient population has aged significantly, with the average age in their clinic now exceeding 50 years and expected to soon exceed 65 years, and how these aging patients experience more comorbidities at younger ages than the general population while their HIV becomes easier to manage with simple regimens.

A panelist discusses how viral suppression in HIV patients means achieving undetectable virus levels (below 50 or 20 copies per ml), which prevents immune system damage and transmission to others, summarized as "undetectable equals untransmissible" (U=U).

Improving adherence to antiretroviral therapy (ART) in youth living with HIV requires interventions that target both family dynamics and any underlying mental illness.

Benjamin K. Chen, MD, PhD, discussed the next steps after the results of his study in genetic tagging showed promise in targeting HIV cells.

Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.

Benjamin Chen, MD, PhD, of the Icahn School of Medicine at Mount Sinai, discusses the implications of his new study involving genetically tagging immune cells with latent HIV.

Women living with HIV in Canada were found to have worse wellbeing when they had adversities related to social determinants of health (SDOH).

Lynae Darbes, PhD, discusses what her research results mean when it comes to implementation of self-testing and counselling for couples vulnerable for HIV.

An expert on the intersection of HIV and menopause, Bridgette J. Picou, LVN, ACLPN, The Well Project, explains the importance of overcoming siloed care for women living with HIV and going through menopause.

Lynae Darbes, PhD, discussed the findings of her study, which found that home-based visits helped to encourage the uptake of HIV testing.

Countries located in sub-Saharan Africa would be most affected by all funding cuts to the international HIV response.

In part 1 of this interview with Katrina Ortblad, ScD, MPH, she addressed bridging gaps in HIV care with pharmacy-based solutions.

The Trump administration has expressed interest in eliminating or changing the Division of HIV Prevention in the CDC, which could introduce gaps in addressing the HIV epidemic.

The HIV prevention division could be rolled into another department of the HHS as soon as the end of the week.

Annie Antar, MD, PhD, discusses how patients with HIV can have different and longer-lasting symptoms of COVID-19.

Annie Antar, MD, PhD, discusses the association between the symptoms of long COVID and HIV status.